Scienture (SCNX) said Tuesday the US Food and Drug Administration approved its new drug application for Arbli, an oral suspension formulation of hypertension drug losartan potassium.
The company said Arbli is indicated for hypertension in patients older than 6 years old, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.
The company also said the product has two patents and is expected to be listed in the FDA's Orange Book.
Scienture said it plans to launch Arbli in the US in Q3.
Shares of the company were up more than 24% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.